Insider trading

Period: 120 months Stock: RYTM + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

240 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

240 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

240 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

240 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
240 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
240 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

240 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
30 May 2019
Van der Ploeg Leonardus H.T. Chief Scientific Officer
Sold, plan not stated
$126.55K 5,000 at 25.31
10.6%
29 May 2019
Van der Ploeg Leonardus H.T. Chief Scientific Officer
Sold, plan not stated
$127.55K 5,000 at 25.51
10.6%
28 May 2019
Van der Ploeg Leonardus H.T. Chief Scientific Officer
Sold, plan not stated
$253.80K 10,000 at 25.38
19.1%
18 Mar 2019
Gottesdiener Keith Michael CEO & President
Sold, plan not stated
$70.50K 2,329 at 30.27
0.5%
15 Mar 2019
Gottesdiener Keith Michael CEO & President
Sold, plan not stated
$239.15K 7,961 at 30.04
1.5%
14 Mar 2019
Gottesdiener Keith Michael CEO & President
Sold, plan not stated
$45.26K 1,506 at 30.05
0.3%
13 Mar 2019
Gottesdiener Keith Michael CEO & President
Sold, plan not stated
$233.93K 7,782 at 30.06
1.5%
27 Feb 2019
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$54.44K 1,814 at 30.01
0.3%
26 Feb 2019
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$19.13K 635 at 30.13
0.1%
19 Feb 2019
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$27.59K 918 at 30.05
0.2%
15 Feb 2019
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$360.30K 12,002 at 30.02
2.2%
13 Feb 2019
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$118.02K 3,934 at 30.00
0.7%
23 Jan 2019
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$3.17K 105 at 30.21
0.0%
22 Jan 2019
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$471.00K 15,674 at 30.05
2.8%
18 Jan 2019
Gottesdiener Keith Michael CEO & President
Sold, plan not stated
$303.55K 10,115 at 30.01
1.8%
16 Jan 2019
Gottesdiener Keith Michael CEO & President
Sold, plan not stated
$19.86K 662 at 30.00
0.1%
16 Jan 2019
Van der Ploeg Leonardus H.T. Chief Scientific Officer
Sold, plan not stated
$6.00K 200 at 30.00
0.5%
3 Dec 2018
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$16.89K 563 at 30.00
0.1%
2 Nov 2018
Van der Ploeg Leonardus H.T. Chief Scientific Officer
Sold, plan not stated
$1.14M 38,000 at 30.09
47.2%
2 Nov 2018
Gottesdiener Keith Michael CEO and President
Sold, plan not stated
$496.32K 16,500 at 30.08
2.8%
25 Sep 2018
Van der Ploeg Leonardus H.T. Chief Scientific Officer
Sold, plan not stated 5×
$947.54K 31,800 at 29.80
37.8%
22 May 2018
ORBIMED ADVISORS LLC 10% owner · indirect
Sold, plan not stated 2×
$595.77K 19,580 at 30.43
0.7%
21 May 2018
ORBIMED ADVISORS LLC 10% owner · indirect
Sold, plan not stated
$1.94M 62,500 at 31.01
2.2%
18 May 2018
ORBIMED ADVISORS LLC 10% owner · indirect
Sold, plan not stated
$2.13M 69,136 at 30.77
2.4%
10 Oct 2017
Viswanathan Ravi 10% owner · indirect
Bought
$9.35M 550,000 at 17.00
12.6%
First buy on file
10 Oct 2017
SANDELL SCOTT D 10% owner · indirect
Bought
$9.35M 550,000 at 17.00
12.6%
First buy on file
10 Oct 2017
MOTT DAVID M 10% owner · indirect
Bought
$9.35M 550,000 at 17.00
12.6%
First buy on file
10 Oct 2017
KERINS PATRICK J 10% owner · indirect
Bought
$9.35M 550,000 at 17.00
12.6%
First buy on file
10 Oct 2017
BASKETT FOREST 10% owner · indirect
Bought
$9.35M 550,000 at 17.00
12.6%
First buy on file
10 Oct 2017
BARRIS PETER J 10% owner · indirect
Bought
$9.35M 550,000 at 17.00
12.6%
First buy on file
10 Oct 2017
BARRETT M JAMES 10% owner · indirect
Bought
$9.35M 550,000 at 17.00
12.6%
First buy on file
10 Oct 2017
Bought
$9.35M 550,000 at 17.00
12.6%
First buy on file
10 Oct 2017
ORBIMED ADVISORS LLC 10% owner · indirect
Bought
$6.04M 355,000 at 17.00
13.9%
First buy on file
10 Oct 2017
Flynn James E 10% owner · indirect
Bought 2×
$6.04M 355,000 at 17.00
313%
First buy on file
10 Oct 2017
MPM BIOVENTURES V, L.P. 10% owner · indirect
Bought
$1.70M 100,000 at 17.00
3.9%
First buy on file
10 Oct 2017
Foley Todd Director · indirect
Bought
$1.70M 100,000 at 17.00
3.9%
First buy on file
10 Oct 2017
PFIZER INC 10% owner
Bought
$680.00K 40,000 at 17.00
2.9%
First buy on file
10 Oct 2017
Meeker David P Director
Bought
$425.00K 25,000 at 17.00
32.8%
First buy on file
10 Oct 2017
Ipsen, S.A. 10% owner · indirect
Bought
$340.00K 20,000 at 17.00
2.5%
First buy on file
5 Oct 2017
BAKER BROS. ADVISORS LP Former 10% owner · indirect
Bought 2×
$15.05M 885,000 at 17.00
89.1%
First buy on file
Showing 201–240 of 240. ← Newer Page 5 of 5